VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd

<< Previous

Bullboard Posts

Next >>

Post by jopatcloon Sep 24, 2024 6:52pm

86 Views

Post# 36239312

On Linkedin post Hugh MacNaught

It is encouraging to note the passage of the Congenital Heart Futures Reauthorization Act of 2024 (H.R. 7189/S. 3757) today in the U.S. House of Representatives. CHFRA is bipartisan legislation that will authorize continued funding of up to $50 million over 5 years for CHD research and surveillance programs at the U.S. Centers for Disease Control and Prevention (CDC). CHFRA will increase support for CHD research, data collection and awareness and lead to better support for CHD patients as they continue along their life journeys. The bill still needs to be passed by Senate which will hopefully occur prior to year end.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading